[go: up one dir, main page]

NO20082628L - Stabile proteinformuleringer - Google Patents

Stabile proteinformuleringer

Info

Publication number
NO20082628L
NO20082628L NO20082628A NO20082628A NO20082628L NO 20082628 L NO20082628 L NO 20082628L NO 20082628 A NO20082628 A NO 20082628A NO 20082628 A NO20082628 A NO 20082628A NO 20082628 L NO20082628 L NO 20082628L
Authority
NO
Norway
Prior art keywords
protein formulations
stable protein
formulations
stable
pathways
Prior art date
Application number
NO20082628A
Other languages
English (en)
Other versions
NO347247B1 (no
Inventor
Manisha M Dali
Charles E Dahlheim
Sunita Borsadia
Vijay H Naringrekar
Rajesh B Gandhi
Manoj Nerurkar
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38057529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082628(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20082628L publication Critical patent/NO20082628L/no
Publication of NO347247B1 publication Critical patent/NO347247B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse angår generelt stabile formuleringer som omfatter CTLA4Ig-molekyler, omfattende frysetørkede og flytende formuleringer for administrering via ulike veier, som for eksempel omfatter veier så som intravenøst (IV) og subkutant (SC), for å behandle immunsystemsykdommer og toleranseinduksjon.
NO20082628A 2005-12-20 2006-12-19 Stabile proteinformuleringer NO347247B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
PCT/US2006/062297 WO2007076354A2 (en) 2005-12-20 2006-12-19 Stable protein formulations

Publications (2)

Publication Number Publication Date
NO20082628L true NO20082628L (no) 2008-07-15
NO347247B1 NO347247B1 (no) 2023-07-31

Family

ID=38057529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082628A NO347247B1 (no) 2005-12-20 2006-12-19 Stabile proteinformuleringer

Country Status (24)

Country Link
US (1) US8476239B2 (no)
EP (1) EP1962886B2 (no)
JP (2) JP5247467B2 (no)
KR (1) KR101378194B1 (no)
CN (3) CN101822820A (no)
AR (2) AR058567A1 (no)
AU (1) AU2006330593B2 (no)
BR (1) BRPI0622256A2 (no)
CA (1) CA2634547C (no)
CL (1) CL2010000816A1 (no)
DK (1) DK1962886T4 (no)
EA (1) EA014232B1 (no)
ES (1) ES2436616T5 (no)
HR (1) HRP20131196T4 (no)
IL (1) IL192104A (no)
NO (1) NO347247B1 (no)
NZ (1) NZ569108A (no)
PE (1) PE20071063A1 (no)
PL (1) PL1962886T6 (no)
PT (1) PT1962886E (no)
RS (1) RS53127B2 (no)
SG (1) SG153832A1 (no)
TW (3) TW200738261A (no)
WO (1) WO2007076354A2 (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076354A2 (en) * 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Stable protein formulations
PT1969007E (pt) 2005-12-20 2013-12-10 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP4183425A1 (en) 2008-10-06 2023-05-24 3-D Matrix Ltd. Tissue plug
EP2445616B1 (en) * 2009-06-23 2018-05-02 GE Healthcare Bio-Sciences AB Simulator device
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
WO2012142434A2 (en) * 2011-04-15 2012-10-18 THE UNITED STATES OF AMERICA, as represented by the secretary, Depart.of Healtth and Human Services Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
EP2709653B1 (en) 2011-04-20 2017-11-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
GEP201706608B (en) 2011-10-07 2017-01-25 Takeda Pharmaceuticals Co 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
AR088379A1 (es) 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con iones metalicos
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
JP2015522024A (ja) 2012-06-29 2015-08-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 糖タンパク質の凝集を低下させるための方法
WO2014008400A2 (en) 2012-07-06 2014-01-09 3-D Matrix, Inc. Fill-finish process for peptide solutions
JP6271536B2 (ja) * 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
WO2014036468A2 (en) 2012-08-31 2014-03-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Aav mediated aquaporin gene transer to treat sjogren's syndrome
SMT202000147T1 (it) 2012-09-07 2020-05-08 Coherus Biosciences Inc Formulazioni acquose stabili di adalimumab
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
EP2855533A4 (en) * 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
RU2016139369A (ru) 2014-03-10 2018-04-10 3-Д Матрикс, Лтд. Композиции самоорганизующихся пептидов
US10369237B2 (en) 2014-03-10 2019-08-06 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
US20170051059A1 (en) 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
US11058768B2 (en) * 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3851445A1 (en) 2014-06-23 2021-07-21 Novartis AG Site specific protein modifications
SG10201902915VA (en) 2014-10-01 2019-04-29 Eagle Biologics Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3207936B1 (en) 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
EP3347031B8 (en) * 2015-09-11 2021-04-28 Nutrition & Biosciences USA 1, LLC A composition comprising a protein and a polyalkoxy fatty compound
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11058769B2 (en) 2015-12-07 2021-07-13 Merck Patent Gmbh Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
KR102840867B1 (ko) 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
CN119386161A (zh) 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
CN108014338A (zh) * 2018-01-22 2018-05-11 安徽未名生物医药有限公司 一种注射用巴利昔单抗冻干粉针及其制备方法
CN112512562A (zh) * 2018-05-25 2021-03-16 雷迪博士实验室有限公司 CTLA4-Ig融合蛋白制剂
US12428464B2 (en) 2018-05-25 2025-09-30 Dr. Reddy's Laboratories Limited Stable fusion protein formulation
EP3813791A2 (en) * 2018-06-26 2021-05-05 Lupin Limited Stable lyophilized dosage form of protein
CN113476484A (zh) * 2018-06-29 2021-10-08 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
CN113396158A (zh) 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
US12466866B2 (en) 2019-01-15 2025-11-11 INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Paris, FRANCE Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
WO2021127525A1 (en) * 2019-12-20 2021-06-24 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
US20240083970A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy’S Laboratories Limited Compositions comprising fusion protein and analytical attributes thereof
JP2024511059A (ja) 2021-03-23 2024-03-12 キングス カレッジ ロンドン Ｎｋｇ２ｄ、ｃｘｃｒ２、およびｄａｐ１０／ｄａｐ１２融合ポリペプチドを含む組成物ならびにその使用方法
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
WO2024069420A2 (en) * 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ262634A (en) * 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
WO2003005465A1 (en) 2001-04-25 2003-01-16 Quallion, Llc Rechargeable lithium battery for tolerating discharge to zero volts
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CZ303959B6 (cs) * 2000-07-03 2013-07-17 Bristol-Myers Squibb Company Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití
JP2004535364A (ja) 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
ATE482716T1 (de) 2001-11-13 2010-10-15 Genentech Inc Zusammensetzungen basierend auf apo2-ligand/ trail und ihre verwendung
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP3178492A1 (en) * 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
RU2353384C2 (ru) 2003-08-04 2009-04-27 Бристол-Маерс Сквибб Компани Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006295340B2 (en) * 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2007076354A2 (en) * 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Stable protein formulations

Also Published As

Publication number Publication date
TW200738261A (en) 2007-10-16
JP2009524595A (ja) 2009-07-02
JP2011246470A (ja) 2011-12-08
RS53127B2 (sr) 2022-06-30
AR097561A2 (es) 2016-03-23
JP5247467B2 (ja) 2013-07-24
TW201008596A (en) 2010-03-01
PT1962886E (pt) 2014-01-07
AU2006330593A1 (en) 2007-07-05
KR20080078070A (ko) 2008-08-26
HRP20131196T4 (hr) 2022-06-10
CN101378773A (zh) 2009-03-04
TWI393575B (zh) 2013-04-21
CA2634547C (en) 2016-10-11
EP1962886B1 (en) 2013-10-16
EP1962886A2 (en) 2008-09-03
IL192104A0 (en) 2008-12-29
NO347247B1 (no) 2023-07-31
ES2436616T5 (es) 2022-05-27
CN101584858A (zh) 2009-11-25
BRPI0622256A2 (pt) 2011-08-09
RS53127B (sr) 2014-06-30
DK1962886T3 (da) 2014-01-13
CN101822820A (zh) 2010-09-08
AR058567A1 (es) 2008-02-13
WO2007076354A3 (en) 2007-08-16
EA014232B1 (ru) 2010-10-29
CL2010000816A1 (es) 2011-02-11
EA200801570A1 (ru) 2008-12-30
PL1962886T6 (pl) 2023-03-13
HRP20131196T1 (hr) 2014-01-31
TW201008595A (en) 2010-03-01
US8476239B2 (en) 2013-07-02
WO2007076354A2 (en) 2007-07-05
JP5538309B2 (ja) 2014-07-02
BRPI0620186A2 (pt) 2010-07-06
PL1962886T3 (pl) 2014-03-31
CN101378773B (zh) 2013-03-13
EP1962886B2 (en) 2022-02-23
HK1114568A1 (en) 2008-11-07
IL192104A (en) 2015-01-29
US20100166774A1 (en) 2010-07-01
SG153832A1 (en) 2009-07-29
NZ569108A (en) 2011-09-30
CA2634547A1 (en) 2007-07-05
AU2006330593B2 (en) 2012-07-26
KR101378194B1 (ko) 2014-03-27
PE20071063A1 (es) 2007-10-24
DK1962886T4 (da) 2022-05-02
ES2436616T3 (es) 2014-01-03

Similar Documents

Publication Publication Date Title
NO20082628L (no) Stabile proteinformuleringer
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
SG127739A1 (en) Use of immuno-regulators
ATE519501T1 (de) Rekombinanter anti-cd40 antikörper und dessen anwendungen
CY1116747T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
NO20072733L (no) Doseformer
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
SE0100043L (sv) Coupling device and medical line set including same
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TNSN05229A1 (en) High concentration antibody and protein formulations
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
WO2007095586A3 (en) Neuronal pain pathway modulators
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
ATE249835T1 (de) Immunoregulator
ECSP003707A (es) Diazepanes
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions
BR0209145A (pt) Vacina contra varìola
WO2009158511A8 (en) Factor viii muteins with reduced immunogenicity
WO2006076504A3 (en) Sialic acid permease system
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung